| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/21/2010 | WO2010009068A2 Cyclohexenyl modulators of chemokine receptor activity |
| 01/21/2010 | WO2010008864A2 Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| 01/21/2010 | WO2010008843A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/21/2010 | WO2010008775A1 Aminopyridopyrazinone derivatives for treating neurodegenerative diseases |
| 01/21/2010 | WO2010008733A2 Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use |
| 01/21/2010 | WO2010008619A2 Extended release pharmaceutical formulations of s-adenosylmethionine |
| 01/21/2010 | WO2010008312A1 Antihypertensive 1-alkyl-2-alkylcarbamoyl-glycerins and a method of the production thereof |
| 01/21/2010 | WO2010008299A1 Novel sulphur containing lipids for use as food supplement or as medicament |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007794A1 Novel spiro compound, and pharmaceutical preparation comprising the same |
| 01/21/2010 | WO2010007788A1 Glycyrrhetinic acid derivative and use thereof |
| 01/21/2010 | WO2010007756A1 Pyridine derivative having ttk inhibition activity |
| 01/21/2010 | WO2010007701A1 Therapeutic agent and test agent for disease with myocardial necrosis |
| 01/21/2010 | WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | WO2010007250A1 D,d-muramyl dipeptides, derived compounds and use thereof for the treatment of atheromatous plaques |
| 01/21/2010 | WO2010007176A1 Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders |
| 01/21/2010 | WO2010007169A1 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| 01/21/2010 | WO2010007099A1 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| 01/21/2010 | WO2010006938A1 Novel heterocyclyl compounds for treatment of cardiovascular disease |
| 01/21/2010 | WO2010006704A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | WO2010006521A1 2-methyl-5h-pyrazolo[1,5-a][3,1]benzoxazin-5-imine compound, the preparation and the use thereof |
| 01/21/2010 | WO2010006496A1 Compounds of estrogen-related receptor modulators and the uses thereof |
| 01/21/2010 | WO2010006485A1 Benzoxazinopyrazoles and their ring-opening compound |
| 01/21/2010 | WO2010006476A1 Myocardial peptide, preparation method and uses thereof |
| 01/21/2010 | WO2010006407A2 Thermal therapy for prevention and/or treatment of cardiovascular diseases and other ailments |
| 01/21/2010 | WO2009143403A8 Combination therapy for the management hypertension |
| 01/21/2010 | WO2009134383A3 Vinyl substituted fatty acids |
| 01/21/2010 | WO2009124184A3 Azabenzanthrones for the treatment of viral infections, cancer or restenosis |
| 01/21/2010 | WO2009117710A3 Methods of treating inflammation |
| 01/21/2010 | WO2009117706A3 Methods of treatment using anti-mif antibodies |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2009018492A3 Micro-rnas that control myosin expression and myofiber identity |
| 01/21/2010 | US20100016938 Diagnosing, monitoring and treating inflammation |
| 01/21/2010 | US20100016833 Devices for the Treatment of Vascular Aneurysm |
| 01/21/2010 | US20100016790 Treatment And Pre-Treatment Device, And Manufacturing Method Therefor, Involving Nitric Oxide |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016446 Stable water-based topical pharmaceutical creams and methods of making and using same |
| 01/21/2010 | US20100016428 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events |
| 01/21/2010 | US20100016423 Use of dronedarone for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016382 Pharmaceutical composition |
| 01/21/2010 | US20100016365 Substituted 4-amino-piperidines |
| 01/21/2010 | US20100016349 Pseudoazulenyl nitrones |
| 01/21/2010 | US20100016341 Aspartyl protease inhibitors containing a tricyclic ring system |
| 01/21/2010 | US20100016336 Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/21/2010 | US20100016332 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 01/21/2010 | US20100016328 Pterin analogs |
| 01/21/2010 | US20100016327 Quinoline compounds |
| 01/21/2010 | US20100016323 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 01/21/2010 | US20100016310 Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
| 01/21/2010 | US20100016305 novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
| 01/21/2010 | US20100016299 Substituted benzoxepino-isoxazoles and use thereof |
| 01/21/2010 | US20100016297 Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| 01/21/2010 | US20100016290 Amorphous polymorph of bazedoxifene acetate |
| 01/21/2010 | US20100016289 Compounds Useful as Antagonists of CCR2 |
| 01/21/2010 | US20100016278 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| 01/21/2010 | US20100016272 Heteroarylacrylamides and their use as pharmaceuticals |
| 01/21/2010 | US20100016260 Agonists of sphingosine-1 phosphate receptor (slp) |
| 01/21/2010 | US20100016259 Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators |
| 01/21/2010 | US20100016246 Food composition for functional foods and nutritional supplements |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100016212 Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide |
| 01/21/2010 | US20100015240 Process for preparing microparticles containing bioactive peptides |
| 01/21/2010 | US20100015229 Pharmaceutical compositions |
| 01/21/2010 | US20100015224 Programmable buoyant delivery technology |
| 01/21/2010 | US20100015145 Use of a compound for reducing the biological effectiveness of IL-6 |
| 01/21/2010 | US20100015121 Inhibiting gs-fdh to modulate no bioactivity |
| 01/21/2010 | US20100015099 Materials and methods relating to treatment of injury and disease to the central nervous system |
| 01/21/2010 | CA2739379A1 Compounds as the estrogen-related receptor modulators and the uses thereof |
| 01/21/2010 | CA2730958A1 Novel sulphur containing lipids for use as food supplement or as medicament |
| 01/21/2010 | CA2730929A1 Pyridone and pyridazone analogues as gpr119 modulators |
| 01/21/2010 | CA2730897A1 Phosphopeptides and use of the same |
| 01/21/2010 | CA2730843A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | CA2730734A1 Deuterated benzylbenzene derivatives and methods of use |
| 01/21/2010 | CA2730610A1 Bicyclic heterocycle derivatives and their use as gpcr modulators |
| 01/21/2010 | CA2730593A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| 01/21/2010 | CA2730534A1 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | CA2730493A1 Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| 01/21/2010 | CA2730281A1 Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| 01/21/2010 | CA2730056A1 Novel heterocyclyl compounds for treatment of cardiovascular disease |
| 01/21/2010 | CA2728636A1 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| 01/21/2010 | CA2728094A1 Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use |
| 01/20/2010 | EP2145884A1 Indoledione derivative |
| 01/20/2010 | EP2145881A1 Antiarrhythmic precursor compounds, methods of synthesis and methods of use |
| 01/20/2010 | EP2145627A1 Use of uridine in combination with choline for the treatment of memory disorders |
| 01/20/2010 | EP2145615A1 Skin-lightening agent containing equol compound as active ingredient |
| 01/20/2010 | EP2144903A1 Substituted deuterium enriched thiophenes for the treatment of hypertension |
| 01/20/2010 | EP1615647B1 Pharmaceutical use of fused 1,2,4-triazoles |
| 01/20/2010 | EP1506214B1 6-11 bicyclic ketolide derivatives |
| 01/20/2010 | EP1458679B1 Pyrrolidine derivatives as prostaglandin modulators |
| 01/20/2010 | EP1443970B1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/20/2010 | EP1117419B1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 01/20/2010 | EP1077994B1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same |
| 01/20/2010 | EP1059940B1 topical compositions comprising an alpha 1-adrenergic blocker FOR TREATING PAINFUL CONDITIONS OF THE ANAL REGION |
| 01/20/2010 | EP1028708B1 Topical compositions for prostaglandin e1 delivery |
| 01/20/2010 | CN201384713Y Piperazine ferulate enteric-coated tablet |
| 01/20/2010 | CN101628905A C-aryl glucoside SGLT2 inhibitors and method |
| 01/20/2010 | CN100582121C 胸腺素β4衍生物及其应用 Thymosin β4 derivative and its applications |
| 01/20/2010 | CN100582120C 21-subunit digoxin derivative and preparation method thereof |
| 01/20/2010 | CN100582087C 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative |